Hypoparathyroidism - Epidemiology Forecast - 2032

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,950	70 Pages	DelveInsight	February, 2022	DEL16978076

Best Price Guarantee
Price	from $3,950
Length	70 Pages
Publisher	DelveInsight
Published Date	February, 2022
SKU	DEL16978076

DelveInsight’s "Hypoparathyroidism—Epidemiology Forecast–2032" report delivers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Hypoparathyroidism Disease Understanding
Hypoparathyroidism (hypoPTH) is a rare condition in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone or lacks biological activity. The parathyroid glands are part of the endocrine system—the network of glands that secrete hormones into the bloodstream, where they travel to various body areas. These hormones regulate the chemical processes (metabolism) that influence various organs and activities within the body. Hormones are involved in numerous vital processes, including regulating heart rate, body temperature, blood pressure, cell differentiation and growth, and modulation of several metabolic processes. Parathyroid hormone (along with vitamin D and the hormone calcitonin, which is produced by the thyroid gland) plays a role in regulating the levels of calcium and phosphorus in the blood and in determining bone growth and bone cell activity. Due to a deficiency of the parathyroid hormone, individuals may exhibit abnormally low levels of calcium in the blood (hypocalcemia) and high levels of phosphorus (hyperphosphatemia).
Continued in the report…..
Hypoparathyroidism Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Hypoparathyroidism, Diagnosed Prevalent Cases of Hypoparathyroidism, Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism, Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism, Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism and Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2019 to 2032.
Hypoparathyroidism Detailed Epidemiology Segmentation
• The total prevalent population of hypoparathyroidism in the 7MM ranges from 280,275 in 2021 growing at a CAGR of 1.23% during the study period [2019–2032].
• The total diagnosed prevalent population of hypoparathyroidism in the United States ranges from 81,320 in 2021 growing at a CAGR of 1.50% during the study period [2019–2032].

• Among the European five countries, United Kingdom had the highest prevalent population of hypoparathyroidism with 34,569 cases, followed by Germany and France in 2021. On the other hand, Spain had the lowest prevalent population.
• Japan had 22,310 prevalent cases of hypoparathyroidism in 2021.
• As per DelveInsight’s analysis, a higher percentage of prevalence was observed for females, in comparison to males, in all the 7MM countries.
• According to DelveInsight’s analysis, it has been observed that hypoparathyroidism prevalence varied across the 7MM countries, based on the age-specific prevalence of the disease. For instance, the highest proportion was observed in the 65+ Years age group in the US, while in the EU-5 countries, people aged 55-64 Years accounted for the maximum patient pool.
• Among the major types of hypoparathyroidism, i.e., Chronic and transient hypoparathyroidism, the former one accounts for a higher number of prevalent cases of hypoparathyroidism.
Scope of the Report
• The report covers the descriptive overview of Hypoparathyroidism, explaining its causes, symptoms, pathophysiology, and genetic basis.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Hypoparathyroidism.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Hypoparathyroidism, Diagnosed Prevalent Cases of Hypoparathyroidism, Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism, Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism, Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism and Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism.

Report Highlights
• 10-Year Forecast of Hypoparathyroidism
• 7MM Coverage
• Total Prevalent Cases of Hypoparathyroidism
• Diagnosed Prevalent Cases of Hypoparathyroidism
• Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism
• Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism
• Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism
• Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism
Key Questions Answered
• What are the disease risk, and burden of Hypoparathyroidism?
• What is the historical Hypoparathyroidism patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Hypoparathyroidism at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Hypoparathyroidism?
• Out of the above-mentioned countries, which country would have the highest incident population of Hypoparathyroidism during the forecast period (2022–2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?
Reasons to buy
The Hypoparathyroidism report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Hypoparathyroidism epidemiology forecast.
• The Hypoparathyroidism epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Hypoparathyroidism epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2019–2032

1 Key Insights
2 Report Introduction
3 Hypoparathyroidism Epidemiology Overview at a Glance
4 Executive Summary of Hypoparathyroidism
5 Key Events
6 Disease Background and Overview: 6.1 Introduction; 6.2 Causes of Hypoparathyroidism; 6.3 Symptoms of Hypoparathyroidism; 6.4 Mechanisms/pathophysiology Hypoparathyroidism; 6.5 Diagnosis of Hypoparathyroidism; 6.5.1 Guidelines for diagnosis and evaluation; 6.5.2 European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults
7 Epidemiology and Patient Population: 7.1 Key Findings; 7.2 Epidemiology Methodology; 7.3 Total Prevalent Cases of Hypoparathyroidism in the 7MM; 7.4 Total Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM; 7.5 Epidemiology of Hypoparathyroidism; 7.6 The United States; 7.6.1 Prevalent Cases of Hypoparathyroidism in the United States; 7.6.2 Diagnosed Prevalent Cases of Hypoparathyroidism in the United States; 7.6.3 Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States; 7.6.4 Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States; 7.6.5 Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States; 7.6.6 Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States; 7.7 EU5; 7.7.1 Prevalent Cases of Hypoparathyroidism in EU5; 7.7.2 Diagnosed Prevalent Cases of Hypoparathyroidism in EU5; 7.7.3 Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5; 7.7.4 Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5; 7.7.5 Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5; 7.7.6 Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5; 7.8 Japan; 7.8.1 Prevalent Cases of Hypoparathyroidism in Japan; 7.8.2 Diagnosed Prevalent Cases of Hypoparathyroidism in Japan; 7.8.3 Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan; 7.8.4 Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan; 7.8.5 Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan; 7.8.6 Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan
8 Appendix: 8.1 Bibliography; 8.2 Report Methodology
9 DelveInsight Capabilities
10 Disclaimer
11 About DelveInsight: Table 1: Summary of Hypoparathyroidism Epidemiology (2019–2032); Table 2: Key Events; Table 3: Acute and chronic manifestations of hypocalcemia and hypoparathyroidism; Table 4: Total Prevalent Cases of Hypoparathyroidism in the 7MM, in ‘000’ (2019–2032); Table 5: Total Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM, in ‘000’ (2019-2032); Table 6: Total Prevalent Cases of Hypoparathyroidism in the United States, in ‘000’ (2019–2032); Table 7: Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in ‘000’ (2019–2032); Table 8: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the US, in ‘000’(2019–2032); Table 9: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in ‘000’ (2019–2032); Table 10: Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in ‘000’ (2019–2032); Table 11: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States, in ‘000’ (2019–2032); Table 12: Total Prevalent Cases of Hypoparathyroidism in EU5, in ‘000’(2019–2032); Table 13: Total Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in ‘000’ (2019–2032); Table 14: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in ‘000’ (2019–2032); Table 15: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in ‘000’ (2019–2032); Table 16: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in ‘000’ (2019–2032); Table 17: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5, in ‘000’ (2019–2032); Table 18: Total Prevalent Cases of Hypoparathyroidism in Japan, in ‘000’ (2019–2032); Table 19: Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in ‘000’ (2019–2032); Table 20: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in ‘000’ (2019–2032); Table 21: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in ‘000’(2019–2032); Table 22: Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in ‘000’ (2019–2032); Table 23: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan, in ‘000’ (2019–2032)Figure 1: Anatomy of Thyroid and parathyroid glands; Figure 2: Symptoms of Hypoparathyroidism; Figure 3: Total Prevalent Cases of Hypoparathyroidism in the 7MM (2019–2032); Figure 4: Total Diagnosed Prevalent Cases of Hypoparathyroidism in the 7MM (2019–2032); Figure 5: Total Prevalent Cases of Hypoparathyroidism in the United States (2019–2032); Figure 6: Diagnosed Prevalent Cases of Hypoparathyroidism in the United States (2019–2032); Figure 7: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the US (2019–2032); Figure 8: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States (2019–2032); Figure 9: Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States (2019–2032); Figure 10: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in the United States (2019–2032); Figure 11: Total Prevalent Cases of Hypoparathyroidism in EU5 (2019–2032); Figure 12: Diagnosed Prevalent Cases of Hypoparathyroidism in EU5 (2019–2032); Figure 13: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5 (2019–2032); Figure 14: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5 (2019–2032); Figure 15: Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5 (2019-2032); Figure 16: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in EU5 (2019–2032); Figure 17: Total Prevalent Cases of Hypoparathyroidism in Japan (2019–2032); Figure 18: Diagnosed Prevalent Cases of Hypoparathyroidism in Japan (2019–2032); Figure 19: Gender-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan (2019–2032); Figure 20: Type-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan (2019–2032); Figure 21: Age-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan (2019–2032); Figure 22: Cause-specific Diagnosed Prevalent Cases of Hypoparathyroidism in Japan (2019–2032)